Vericiguat for the treatment of heart ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Title :
Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options
Author(s) :
Hulot, Jean-Sébastien [Auteur correspondant]
CIC - HEGP [CIC 1418]
Paris-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)]
Trochu, Jean-Noël [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
ITX - unité de recherche de l'institut du thorax [ITX]
Donal, Erwan [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Laboratoire Traitement du Signal et de l'Image [LTSI]
Galinier, Michel [Auteur]
Faculté de Médecine [Rangueil]
Logeart, Damien [Auteur]
Université Paris Cité [UPCité]
Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
De Groote, Pascal [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Juilliere, Yves [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
CIC - HEGP [CIC 1418]
Paris-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)]
Trochu, Jean-Noël [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
ITX - unité de recherche de l'institut du thorax [ITX]
Donal, Erwan [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Laboratoire Traitement du Signal et de l'Image [LTSI]
Galinier, Michel [Auteur]
Faculté de Médecine [Rangueil]
Logeart, Damien [Auteur]
Université Paris Cité [UPCité]
Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
De Groote, Pascal [Auteur]

Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Juilliere, Yves [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Journal title :
Expert Opinion on Pharmacotherapy
Pages :
1847-1855
Publisher :
Taylor & Francis
Publication date :
2021-09-22
ISSN :
1465-6566
English keyword(s) :
cGMP pathway
heart failure (hf)
heart failure hospitalization (hfh)
heart failure with reduced ejection fraction (hfref)
reduced left ventricular ejection fraction (lvef)
soluble guanylate cyclase (sGC)
sGC stimulator
ventricular remodeling
vericiguat
worsening chronic heart failure (WCHF))
heart failure (hf)
heart failure hospitalization (hfh)
heart failure with reduced ejection fraction (hfref)
reduced left ventricular ejection fraction (lvef)
soluble guanylate cyclase (sGC)
sGC stimulator
ventricular remodeling
vericiguat
worsening chronic heart failure (WCHF))
HAL domain(s) :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Cardiologie et système cardiovasculaire
Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie
Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie
English abstract : [en]
Introduction The significant morbidity and mortality in patients with heart failure (HF), notably in the most advanced forms of the disease, justify the need for novel therapeutic options. In the last year, the soluble ...
Show more >Introduction The significant morbidity and mortality in patients with heart failure (HF), notably in the most advanced forms of the disease, justify the need for novel therapeutic options. In the last year, the soluble guanylate cyclase (sGC) stimulator, vericiguat, has drawn the attention of the medical community following the report of reduced clinical outcomes in patients with worsening chronic HF (WCHF).Areas Covered The authors review the available data on the mechanism of action of vericiguat (cyclic guanosine monophosphate (cGMP) pathway), its clinical development program, its role in HF management, and its future positioning in the therapeutic recommendations.Expert opinion cGMP deficiency has deleterious effects on the heart and contributes to the progression of HF. Different molecules, including nitric oxide (NO) donors, phosphodiesterase inhibitors, and natriuretic peptides analogues, target the NO-sCG-cGMP pathway but have yielded conflicting results in HF patients. Vericiguat acts as a sGC stimulator thus targeting the NO-sGC-cGMP pathway by a different mechanism that complements the current pharmacotherapy for HF. Vericiguat has shown an additional statistical add-on therapy efficacy by reducing morbi-mortality in patients with WCHF. A better evaluation of HF severity might be an important determinant to guide the use of vericiguat among the available therapies.Show less >
Show more >Introduction The significant morbidity and mortality in patients with heart failure (HF), notably in the most advanced forms of the disease, justify the need for novel therapeutic options. In the last year, the soluble guanylate cyclase (sGC) stimulator, vericiguat, has drawn the attention of the medical community following the report of reduced clinical outcomes in patients with worsening chronic HF (WCHF).Areas Covered The authors review the available data on the mechanism of action of vericiguat (cyclic guanosine monophosphate (cGMP) pathway), its clinical development program, its role in HF management, and its future positioning in the therapeutic recommendations.Expert opinion cGMP deficiency has deleterious effects on the heart and contributes to the progression of HF. Different molecules, including nitric oxide (NO) donors, phosphodiesterase inhibitors, and natriuretic peptides analogues, target the NO-sCG-cGMP pathway but have yielded conflicting results in HF patients. Vericiguat acts as a sGC stimulator thus targeting the NO-sGC-cGMP pathway by a different mechanism that complements the current pharmacotherapy for HF. Vericiguat has shown an additional statistical add-on therapy efficacy by reducing morbi-mortality in patients with WCHF. A better evaluation of HF severity might be an important determinant to guide the use of vericiguat among the available therapies.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Collections :
Source :
Files
- document
- Open access
- Access the document
- Hulot_et%20al_2021_Vericiguat%20for%20the%20treatment%20of%20heart%20failure_accepted.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- Hulot_et%20al_2021_Vericiguat%20for%20the%20treatment%20of%20heart%20failure_accepted.pdf
- Open access
- Access the document